Development of a new vaccine approach against hemolytic uremic syndrome using genetically modified Bacillus subtilis strain expressing Stx2 EHEC toxin. / Desenvolvimento de uma nova estratégia vacinal contra síndrome hemolítica urêmica utilizando linhagens geneticamente modificadas de Bacillus subtilis capazes de expressar a toxina Stx2 de EHEC.
AUTOR(ES)
Priscila Aparecida Dal Pozo Gomes
DATA DE PUBLICAÇÃO
2008
RESUMO
The Hemolytic Uremic Syndrome (HUS) is the main disease associated with infections with Shiga toxin (Stx) - producing Escherichia coli strain and no effective vaccine or treatment exist. The Stx toxin consist of an enzymatically active A subunit and a pentameric B subunit responsible toxin binding to host cells. In this work we propose the use of Bacillus subtilis, a harmless spore form bacteria as a vaccine vehicle for the expression atoxic forms of Stx2, under the control of stress inducible (PgsiB) promoter. BALB/c mice immunized with vegetative cells and spores of the B. subtilis vaccine strain using different immunization routes elicited low specific antibody levels at serum (IgG) or fecal extracts (IgA). We also investigated the immunogenic potencial of StxB purified from recombinant E. coli strain, but the induced anti-StxB antibodies did not neutralize the native toxin. The results indicate that alternative expression system or the incorporation of the adjuvants are required for the generation of vaccine formulation active against HUS.
ASSUNTO(S)
shiga toxin hemolytic uremic syndrome bacillus subtilis síndrome hemolítica urêmica toxina de shiga bacillus subtilis
Documentos Relacionados
- Aplicação de linhagens geneticamente modificadas de Bacillus subtilis no desenvolvimento de vacinas de mucosas contra patógenos entéricos.
- Antibody Response to Shiga Toxins Stx2 and Stx1 in Children with Enteropathic Hemolytic-Uremic Syndrome
- Vacinas de administração oral contra diarréia associada à Escherichia coli enteropatogênica baseada em linhagens geneticamente modificadas de Bacillus subtilis
- Desenvolvimento de estratégias vacinais contra tumores induzidos pelo vírus do papiloma humano tipo 16 (HPV-16) baseadas em linhagens geneticamente modificadas de Bacillus subtilis.
- Shiga Toxin-Producing Escherichia coli Infection and Antibodies against Stx2 and Stx1 in Household Contacts of Children with Enteropathic Hemolytic-Uremic Syndrome